In conclusion, FDG-PET/CT did not detect additional lymphoma involvement with modification of clinical stage. However, in 11% of patients (5 of 44), PET/CT identified visceral lesions that required further clinical workup and/or treatment. Further studies are required to address clinical usefulness of PET/CT in CTCL. 
P
ain is a common feature of cancer with an estimated prevalence rate between 52% and 77%. 1 Itch is the most common dermatologic symptom and is also a common feature of lymphoma. 2 However, no studies have been performed examining the prevalence rates of pain and itch in common skin cancers. Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the 2 most common types of nonmelanoma skin cancer (NMSC). They have a rapidly increasing incidence in the United States, with nearly 4 million new cases of NMSC diagnosed each year. 3 The purpose of the present study was to assess the prevalence and intensity of pain and itch among the 2 most common skin cancers.
Methods. Data for this institutional review boardapproved study were prospectively collected on a total of 576 biopsy-proven NMSCs from 478 patients with either BCC or SCC seen in the dermatologic surgery department at Wake Forest University Baptist Medical Center from July 2010 to March 2011. Patients rated their pain and itch intensity on a visual analog scale from 0 (least intense) to 10 (most intense). A multiple logistic regression model was fit to examine the relationship of pain and itch with BCC and SCC using age, sex, chronic pain-or itch-related conditions, tumor size, and depth of invasion as covariates. A subanalysis was also performed to compare SCC in situ vs invasive SCC.
Results.
Of the 505 patients approached, 478 completed the study. The mean (SD) age was 68.8 (12.7) years (age range, 27-94 years), and most patients were male (304 men, 174 women). There were 353 biopsy-proven SCCs and 223 BCCs.
Itch was the most common symptom reported in both skin cancers (43.5% of SCCs and 33.4% of BCCs). This difference was not statistically significant.
The prevalence of pain was 39.8% (95% CI, 35.4%-44.2%) in SCC and 17.7% (95% CI, 13.4%-21.9%) in BCC. A patient's pain score was a highly significant predictor of having an SCC as opposed to a BCC (P Ͻ.001). For each point increase on the VAS in pain, there was a 30% increase in the odds of having an SCC compared with having a BCC (Figure, A) . Further analysis revealed that patients presenting with a pain score higher than 2 had a nearly 4-fold increase in the likelihood of having an SCC compared with a BCC (odds ratio [OR], 3.94 [95% CI, 2.49-6.23) (PϽ .001).
To account for potential intraindividual differences in patients with multiple skin cancers, data were stratified into 2 groups, patients with 1 skin cancer vs those with 2 or more skin cancers. Analyses were repeated in each group, and comparable results were obtained, suggesting no difference between these groups. Interestingly, pain did not significantly differ in patients with SCC in situ compared with invasive types of SCC (P=.47).
Comment. Our findings reveal that pain and itch are common symptoms of NMSC. A previous study reported tenderness in SCC, 4 but to our knowledge, ours is the first study to assess the prevalence of pain and itch and their intensities in NMSC. Specifically, we have shown the intensity of pain to be a unique factor to help in differentiating SCC from BCC. This finding is of significant clinical utility in the diagnosis and treatment of NMSCs. With an increasingly aging population, patients often present with numerous BCCs and SCCs, and it is often difficult for the clinician to prioritize lesion biopsy and removal. Thus, there is a need for better clinical tools to aid the physician in selecting lesions most likely to be SCCs,
Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis
A cute generalized pustular psoriasis (GPP) is a rare, life-threatening form of psoriasis; therefore, rapidly effective treatment is needed. Etanercept was beneficial in GPP, 1 but the benefit of infliximab or adalimumab was less frequently reported. 2 The purpose of the present study was to evaluate the efficacy and safety of tumor necrosis factor (TNF) inhibitors in a series of patients with GPP.
Methods.
A national, multicenter, retrospective study was conducted among patients who were seen in French university hospital dermatology departments and who received TNF inhibitors for GPP flaring within the postlabeling period. The study received approval from the institutional review board (Comité d'Evaluation de l'Ethique des projets de Recherche Biomédicale, Paris Nord, No. 12-017).
Patients included in the study had abrupt onset of generalized inflammatory erythema with successive waves of diffuse sterile pustules with subsequent desquamation accompanied by marked asthenia, high-grade fever, and hyperleukocytosis. They also had documented 
